FDA Awards Merck KGaA, Pfizer Breakthrough Therapy Designation for Avelumab

Avelumab is an anti-PD-L1 IgG1 monoclonal antibody designed for use with difficult-to-treat cancers. Read More

FDA Grants Expanded Clearance to Entellus for XprESS Multi-Sinus Dilation System

The treatment is now indicated for certain pediatric populations. Read More
The Solutions Center